<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Georgoulias, V.</style></author><author><style face="normal" font="default" size="100%">Kouroussis, C.</style></author><author><style face="normal" font="default" size="100%">Androulakis, N.</style></author><author><style face="normal" font="default" size="100%">Kakolyris, S.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Papadakis, E.</style></author><author><style face="normal" font="default" size="100%">Bouros, D.</style></author><author><style face="normal" font="default" size="100%">Apostolopoulou, F.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Agelidou, A.</style></author><author><style face="normal" font="default" size="100%">Hatzakis, K.</style></author><author><style face="normal" font="default" size="100%">Kalbakis, K.</style></author><author><style face="normal" font="default" size="100%">Kotsakis, A.</style></author><author><style face="normal" font="default" size="100%">Vardakis, N.</style></author><author><style face="normal" font="default" size="100%">Vlachonicolis, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">1999</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1999</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033014303&amp;partnerID=40&amp;md5=fd098621632fb84876718c41aeefbae0</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">914 - 920</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose: To evaluate the tolerance and efficacy of the combination of docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Fifty-one chemotherapy-naive patients with NSCLC were treated with gemcitabine 900 mg/m2 intravenously on days 1 and 8 and docetaxel 100 mg/m2 intravenously on day 8 with granulocyte colony-stimulating factor (150 μg/m2, subcutaneously) support from day 9 to day 15. Treatment was repeated every 3 weeks. Results: The patients' median age was 64 years. The World Health Organization performance status was 0 to 1 in 39 patients and 2 in 12 patients. Fifteen patients (29%) had stage IIIB disease, and 36 (71%) had stage IV; histology was mainly squamous cell carcinoma (59%). A partial response was achieved in 19 patients (37.5%; 95% confidence interval, 24% to 50%); stable disease and progressive disease were each observed in 16 patients (31.4%). The median duration of response and the time to tumor progression were 5 and 6 months, respectively. The median survival was 13 months, and the actuarial 1-year survival was 50.7%. Grade 4 anemia and thrombocytopenia were rare (2%). Four patients (8%) developed grade 3 or 4 neutropenia, and all were complicated with fever; there was no treatment-related death. Grade 3 or 4 diarrhea occurred in three patients (6%), grade 2 or 3 neurotoxicity in four patients (8%), grade 2 or 3 asthenia in 10 patients (20%), and grade 2 or 3 edema in 10 patients (20%). Conclusion: The combination of docetaxel/gemcitabine is well tolerated, can be used for outpatients, and is active for the treatment of advanced NSCLC. This treatment merits further comparison with other cisplatin- or carboplatin-based combinations.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :123Export Date: 21 February 2017</style></notes></record></records></xml>